Pei-Mei Chai
Overview
Explore the profile of Pei-Mei Chai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu Y, Lin P, Teng W, Hsieh Y, Chen W, Su C, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456553
Background: The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for lenvatinib plus pembrolizumab...
2.
Lee C, Chen H, Tsai P, Lee W, Wang C, Yu M, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):354.
PMID: 39031214
Background: Patients with autoimmune diseases (AD) generally carry an increased risk of developing cancer. However, the effect of AD in hepatocellular carcinoma (HCC) patients receiving surgical treatment is uncertain. The...
3.
Lin P, Hsu Y, Kao Y, Teng W, Hsieh Y, Chen W, et al.
Am J Cancer Res
. 2024 Apr;
14(3):1306-1315.
PMID: 38590407
For advanced hepatocellular carcinoma (HCC), the best second-line treatment after first-line treatment with sorafenib is unclear. This study aimed to compared the efficacy of second-line regorafenib (a tyrosine kinase inhibitor)...
4.
Su C, Teng W, Shen E, Huang B, Lin P, Hou M, et al.
Oncologist
. 2024 Mar;
29(7):e922-e931.
PMID: 38530254
Background: Atezolizumab plus bevacizumab (atezo-bev) has been recommended for advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is recognized for its excellent local tumor control. The efficacy and safety...
5.
Chan K, Lai Y, Hung H, Lee J, Cheng C, Wang Y, et al.
J Hepatocell Carcinoma
. 2023 Feb;
10:281-290.
PMID: 36845025
Background: Tyrosine kinase inhibitors (TKIs) remain the primary therapeutic option for patients with advanced-stage hepatocellular carcinoma (HCC). However, the selection of a suitable TKI is an issue in real-world clinical...
6.
Su C, Teng W, Lin P, Jeng W, Chen K, Hsieh Y, et al.
Cancer Med
. 2022 Dec;
12(6):7077-7089.
PMID: 36468578
Background: Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first-line therapy. Real-world studies comparison of efficacy and safety in these two regimens...
7.
Huang S, Chong S, Huang C, Hsu H, Pan K, Hung C, et al.
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140381
Sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). However, there is no evidence for a response of different target lesions to sorafenib administration. Therefore, we aimed to evaluate...
8.
Teng W, Lin C, Su C, Lin P, Hsieh Y, Chen W, et al.
Am J Cancer Res
. 2022 May;
12(4):1899-1911.
PMID: 35530282
Immune checkpoint inhibitors (ICIs) with atezolizumab plus bevacizumab are promising agents for unresectable hepatocellular carcinoma (HCC). We tried to guide the treatment based on recent developed CRAFITY score combining with...
9.
Lin P, Teng W, Jeng W, Chen W, Hsieh Y, Huang C, et al.
Diagnostics (Basel)
. 2022 Mar;
12(3).
PMID: 35328217
Background and Aims: The Albumin-Bilirubin (ALBI) grade is a good index for liver function evaluation and is also associated with the outcomes of hepatocellular carcinoma patients receiving TACE. However, the...